Compare Stocks: REPL, ACAD, IOVA, and TLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.29 -0.6%	$27.64	$19.69 ▼ $30.96	$4.73B	0.86	1.26 million shs	5.48 million shs
IOVA Iovance Biotherapeutics	$10.25 +2.3%	$6.88	$1.76 ▼ $10.98	$4.54B	0.83	12.76 million shs	22.85 million shs
REPL Replimune Group	$13.07 +1.6%	$12.70	$1.50 ▼ $16.33	$1.21B	0.94	2.01 million shs	2.15 million shs
TLX Telix Pharmaceuticals	$12.59 +0.6%	$11.30	$6.28 ▼ $13.11	$4.25B	-0.17	308,960 shs	187,336 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.58%	-1.94%	-9.67%	+26.23%	+12.77%
IOVA Iovance Biotherapeutics	+2.30%	+19.19%	+28.29%	+162.08%	+361.71%
REPL Replimune Group	+1.55%	+1.16%	-11.75%	+28.26%	+128.90%
TLX Telix Pharmaceuticals	+0.64%	+11.51%	+3.88%	+24.78%	+34.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.29 -0.6%	$27.64	$19.69 ▼ $30.96	$4.73B	0.86	1.26 million shs	5.48 million shs
IOVA Iovance Biotherapeutics	$10.25 +2.3%	$6.88	$1.76 ▼ $10.98	$4.54B	0.83	12.76 million shs	22.85 million shs
REPL Replimune Group	$13.07 +1.6%	$12.70	$1.50 ▼ $16.33	$1.21B	0.94	2.01 million shs	2.15 million shs
TLX Telix Pharmaceuticals	$12.59 +0.6%	$11.30	$6.28 ▼ $13.11	$4.25B	-0.17	308,960 shs	187,336 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.58%	-1.94%	-9.67%	+26.23%	+12.77%
IOVA Iovance Biotherapeutics	+2.30%	+19.19%	+28.29%	+162.08%	+361.71%
REPL Replimune Group	+1.55%	+1.16%	-11.75%	+28.26%	+128.90%
TLX Telix Pharmaceuticals	+0.64%	+11.51%	+3.88%	+24.78%	+34.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	25.91% Upside
IOVA Iovance Biotherapeutics	2.45	Hold	$9.11	-11.11% Downside
REPL Replimune Group	2.60	Moderate Buy	$12.00	-8.19% Downside
TLX Telix Pharmaceuticals	2.86	Moderate Buy	$20.40	62.03% Upside

Current Analyst Ratings Breakdown

Latest REPL, ACAD, IOVA, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$13.00 ➝ $15.00
9/15/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/14/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/26/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$20.00 ➝ $21.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/24/2026	IOVA Iovance Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $10.00
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$4.00 ➝ $7.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.39	$0.88 per share	30.94	$7.25 per share	3.76
IOVA Iovance Biotherapeutics	$263.50M	17.62	N/A	N/A	$1.76 per share	5.82
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A
TLX Telix Pharmaceuticals	$803.79M	5.32	$0.04 per share	296.58	$1.23 per share	10.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	12.29	27.85	N/A	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	157.38	N/A	N/A	N/A	N/A	N/A

Latest REPL, ACAD, IOVA, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
REPL Replimune Group	1.00	5.23	5.23
TLX Telix Pharmaceuticals	1.16	2.01	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
IOVA Iovance Biotherapeutics	77.03%
REPL Replimune Group	92.53%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
IOVA Iovance Biotherapeutics	7.80%
REPL Replimune Group	5.40%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.31 million	127.16 million	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
REPL Replimune Group	465	93.80 million	88.73 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A

REPL, ACAD, IOVA, and TLX Headlines

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Hits New 12-Month High - Should You Buy?

September 17 at 4:41 AM | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for Telix Pharmaceuticals (NASDAQ:TLX)

September 17 at 1:30 AM | americanbankingnews.com

Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement

September 16 at 11:57 PM | seekingalpha.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Time to Sell?

September 16 at 10:59 AM | marketbeat.com

Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Up 10.22%

September 16 at 3:50 AM | aaii.comA

Telix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from Wedbush

September 16 at 1:36 AM | americanbankingnews.com

ASX biotech expands diagnostics portfolio after FDA approval

September 15, 2026 | morningstar.com.auM

Are Telix shares a buy after its big US FDA news?

September 15, 2026 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Earns Buy Rating from HC Wainwright

September 15, 2026 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year High - Time to Buy?

September 15, 2026 | marketbeat.com

Telix Pharmaceuticals Receives FDA Approval for Brain Cancer Imaging Drug Pixclara

September 14, 2026 | finance.yahoo.com

Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What Happened

September 14, 2026 | marketbeat.com

FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug

September 14, 2026 | benzinga.com

FDA green light for Telix’s brain cancer imaging drug Pixclara

September 14, 2026 | thepharmaletter.comT

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

September 14, 2026 | finance.yahoo.com

Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children

September 14, 2026 | rttnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from Wedbush

September 14, 2026 | marketbeat.com

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

September 14, 2026 | globenewswire.com

Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

September 13, 2026 | fool.com.au

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

September 13, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, ACAD, IOVA, and TLX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$27.29 -0.16 (-0.58%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$27.22 -0.07 (-0.26%)

As of 09/18/2026 07:55 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$10.25 +0.23 (+2.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.22 -0.03 (-0.30%)

As of 09/18/2026 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Replimune Group NASDAQ:REPL

$13.07 +0.20 (+1.55%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.07 0.00 (0.00%)

As of 09/18/2026 07:48 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$12.59 +0.08 (+0.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.60 +0.02 (+0.12%)

As of 09/18/2026 07:30 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, ACAD, IOVA, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, ACAD, IOVA, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, ACAD, IOVA, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, ACAD, IOVA, and TLX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Iovance Biotherapeutics NASDAQ:IOVA

Replimune Group NASDAQ:REPL

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, ACAD, IOVA, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, ACAD, IOVA, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, ACAD, IOVA, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, ACAD, IOVA, and TLX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Iovance Biotherapeutics NASDAQ:IOVA

Replimune Group NASDAQ:REPL

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools